Listed for 3 consecutive years! Medicilon won the "Top 20 Chinese R&D CRO Enterprises in 2022"

On December 9, 2022, the "2022 High-Quality Development Conference of the Great Health Industry and the 7th China Pharmaceutical R&D Innovation Summit" jointly organized by Yaozhi.com and China Pharmaceutical Industry Journal Publisher was successfully held online.  During the summit, the much-anticipated "2022 China Drug R&D Strength Ranking List" was grandly released.  Shanghai Medicilon Inc. (Medicilon), as a one-stop pharmaceutical preclinical R&D service platform in China, was once again selected as one of the "Top 20 Chinese R&D CRO Enterprises in 2022" by virtue of its solid R&D strength.  This is the 3rd consecutive year that Medicilon has won this honorary title!

The "Top 20 Chinese R&D CRO Enterprises in 2022" list is selected strictly based on the following 10 indicators: company's total annual revenue, annual revenue growth, net profit, net profit growth, R&D investment, R&D investment growth, employee size, employee size growth, brand reputation, and segment leader.  The list represents the highest level in the pharmaceutical CRO/CDMO industry.